The national patient library: Evidence-based information for consumers

International Journal of Technology Assessment in Health Care

Volumn 14, Issue 1, 1998, Pages 81-96

  Lerner, Jeffrey C ^a  

^a ECRI ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CANCER CHEMOTHERAPY; COMPUTER NETWORK; CONSUMER; LIBRARY; MANAGED CARE; MEDICAL INFORMATION; REVIEW; STAFF;

EID: 0031911690     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300010540     Document Type: Review

References (18)

1. American Association of Health Plans. Our philosophy of care. 1996.
2. Avorn, J., Chen, M. & Hartley, R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Journal of Medicine, 1982, 73, 4-8.
3. CDP Technologies. Combined health information database: field guide.
4. Council on Competitiveness. Highway to health: transforming U.S. health care in the information age. Washington, DC: Council on Competitiveness, 1996.
5. de Jong, R. H. Backfire: AHCPR practice guideline for acute low back pain. Journal of the South Carolina Medical Association, 1995, 91, 465-68.
6. ECRI. ACOG lists ob/gyn technologies needing more study. Health Technology Trends, 1997, 9, in press.
7. ECRI. High-dose chemotherapy with autologous bone marrow transplantation and/or blood cell transplantation for the treatment of metastatic breast cancer [technology assessment report]. Plymouth Meeting (PA): ECRI, 1996.
8. ECRI. High-dose chemotherapy with bone marrow transplant for metastatic breast cancer: Patient reference guide. Plymouth Meeting (PA): ECRI, 1996.
9. ECRI telephone survey, 1991.
10. ECRI and the U.S. Agency for Health Care Policy and Research. Healthcare technology choices under managed care: Communicating directly with patients and their clinicians. A conference on critical issues. November 7-8, 996. Plymouth Meeting (PA): ECRI, 1996.
11. Eddy, D. M. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology, 1992, 0, 57-70.
12. Empire Blue Cross and Blue Shield. Empire Blue Cross and Blue Shield announces new policy for evaluating experimental and investigational procedures for terminally ill. Outside experts to be used to assess effectiveness of requested procedures [press release]. January 77, 1997.
13. Ferguson, J. H., Dubinsky, M., & Kirsch, P. J. Court-ordered reimbursement for unproven medical technology: Circumventing technology assessment. JAMA, 1993, 269, 2116-21.
14. Fleming, T. R., & DeMets, D. L. Surrogate end points in clinical trials: Are we being misled? Annals of Internal Medicine, 1996, 125, 605-13.
15. Foundation for Informed Medical Decision Making, Inc. Shared decision-making programs: Providing patients and their physicians help with the medical decision-making process [cited Jan 7, 997]. Available from: http://www.dartmouth.edu/dms/cecs/dimdm/.
16. Gotzsche, P. C., Liberati, A., Torri, V., et al. Beware of surrogate outcome measures. International Journal of Technology Assessment in Health Care, 1996, 12, 238-46.
17. Hyde, C. J. Using the evidence: A need for quantity, not quality? International Journal of Technology Assessment in Health Care, 1996, 12, 280-87.
18. Kennedy, M. A tool for patient education. Health Data Management, February 1996, 61-65.